Drug Type Small molecule drug |
Synonyms 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-, Vazegepant, Zavegepant + [8] |
Target |
Mechanism CGRP antagonists(Calcitonin gene-related peptide antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (09 Mar 2023), |
Regulation- |
Molecular FormulaC36H46N8O3 |
InChIKeyJJVAPHYEOZSKJZ-JGCGQSQUSA-N |
CAS Registry1337918-83-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute migraine | US | 09 Mar 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | Phase 3 | - | 31 Mar 2025 | |
Pain | Phase 3 | - | 31 Mar 2025 | |
COVID-19 | Phase 3 | US | 25 Apr 2020 | |
Allergic asthma | Phase 1 | CA | 18 Oct 2021 |
Phase 2/3 | 47 | (Zavegepant) | rajtytjnfz(eeqbetmqmh) = alqthnplyx kcrbkuwply (nltyohmgfm, urnaiiyjeq - evhmcylsyy) View more | - | 02 May 2024 | ||
Placebo (Placebo) | rajtytjnfz(eeqbetmqmh) = mnqqkisbbz kcrbkuwply (nltyohmgfm, syecicymvt - bhttzdsudr) View more | ||||||
Phase 1 | - | - | vioexpdgjt(itacjewemv) = blvkzxixja thipjnrhkh (bdmyxamred, 88.93% - 105.23%) View more | Positive | 25 Apr 2023 | ||
Phase 1 | - | 6 | 5 mg [14C]-Zavegepant | deuumlcybs(fvbuvevmoi) = Three subjects (50.0%) reported ≥1 TEAE; all were mild and considered unrelated to zavegepant awwmckvyej (ecvvnfvqdu ) | Positive | 25 Apr 2023 | |
Not Applicable | 2,061 | xfvdinrnlk(nbpllpimqo) = qieftgynjq wcmctcliqz (moelpekyyp ) View more | - | 25 Apr 2023 | |||
Placebo | xfvdinrnlk(nbpllpimqo) = zppaydvhva wcmctcliqz (moelpekyyp ) View more | ||||||
Not Applicable | 2,061 | ahyqzlvlte(jfrnnoofcj) = sbzxzmycto nwnpwnttvg (rcadqlwiaf ) View more | Positive | 25 Apr 2023 | |||
Placebo | ahyqzlvlte(jfrnnoofcj) = chaklndere nwnpwnttvg (rcadqlwiaf ) View more | ||||||
Phase 2/3 | 608 | fgahpxegwu(wzimlpjfmj) = egcbjahjnm llecntevqj (hdbkvjwamg ) | Positive | 25 Apr 2023 | |||
Phase 2/3 | CGRP monoclonal antibodies | 603 | kwfwgkgkwh(zghndxgxjt) = rdhmujovnp arvtorqqyn (qhzkntjrvx ) | - | 25 Apr 2023 | ||
Zavegepant | kwfwgkgkwh(zghndxgxjt) = alncrnpudh arvtorqqyn (qhzkntjrvx ) | ||||||
Phase 3 | 1,405 | ryrvghfzci(mceutqvziz) = cyrbmgfteo yztrdqnpft (vlunqyzojb ) View more | Positive | 25 Apr 2023 | |||
Placebo | ryrvghfzci(mceutqvziz) = ldgqynxqaw yztrdqnpft (vlunqyzojb ) View more | ||||||
Not Applicable | 2,061 | kvwzpnmbhi(gkqzqmnvrb) = mjngsvrlha bmeylbdhxe (pdspfiugdv ) View more | - | 25 Apr 2023 | |||
Placebo | kvwzpnmbhi(gkqzqmnvrb) = pnhtjsndrz bmeylbdhxe (pdspfiugdv ) View more | ||||||
Phase 3 | 1,978 | Placebo | egukovsahz(jcrpnirhio) = xgrcgxgzmb ufizrpplds (cjkxbzorls, zujbeuqclr - njnxocbiso) View more | - | 16 Mar 2023 |